In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause

Ann Intern Med. 2021 May;174(5):JC53. doi: 10.7326/ACPJ202105180-053. Epub 2021 May 4.

Abstract

Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22-31. 33338413.

Publication types

  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glomerular Filtration Rate
  • Glucosides
  • Humans
  • Kidney
  • Renal Insufficiency, Chronic* / complications

Substances

  • Benzhydryl Compounds
  • Glucosides
  • dapagliflozin